LON:BVXP

Bioventix Interim Earnings Report

Bioventix logo
GBX 1,688 +13.00 (+0.78%)
As of 10:07 AM Eastern

Bioventix EPS Results

Actual EPS
GBX 69.38
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioventix Revenue Results

Actual Revenue
$6.16 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bioventix Announcement Details

Quarter
Interim
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Bioventix Earnings Headlines

Millionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon.
Hedge fund trader Larry Benedict went 13-for-13 in Q1 2025 - not a single losing trade - and finished the year with a 279% return on cash while the S&P returned 15%. Now Benedict says the SpaceX IPO has triggered the 'Final Phase of Elon's Master Plan,' with billions potentially flowing into a single ticker. He's revealing the name and ticker today, free of charge.tc pixel
Peter Harrison Spends UK£39k On Bioventix Stock
See More Bioventix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioventix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioventix and other key companies, straight to your email.

About Bioventix

Bioventix (LON:BVXP) creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.

View Bioventix Profile